If you do use the phone, please use the internet portal to follow the slides and ask questions as we will only be taking questions online and not via phone.
This group call will be a power point flip presentation with an opportunity for Q and A.
Once logged into the portal and the presentation starts you should also see a question box. At any time during the presentation, you can submit a question. If you are having audio issues, you can dial into the presentation with the numbers provided. Thanks and hope to see you on the call.
MORE ABOUT WILLOW
Willow is a biotechnology company focused on revolutionizing industrial manufacturing of core ingredients and other high value products that have traditionally been derived from plants.
Producing life changing compounds from nature has been happening for hundreds of years. Aspirin was first created from the bark of the Willow tree (hence the name). Penicillin was first discovered as mould growing on a petri dish but is manufactured today using biosynthetic methods.
Willow’s proprietary technology allows the Company to target high value and traditionally difficult-to-harvest ingredients for pharma, consumer care, flavor and fragrance, as well as the food and beverage industries. The Company can deliver higher purity, more consistent, and more sustainable ingredients within a shorter time frame and at lower costs. In addition, Willow provides significant environmental and sustainability benefits vs current incumbent solutions for plant cultivation.
Willow is initially targeting the fast-growing cannabinoid ingredient marketplace. This significant addressable global market is currently valued at $20 billion and is estimated to hit $100 billion by 2028. Their first product launch (2021) is targeting CBG, considered a health and wellness molecule. In just over two years, Willow has gone from proof of concept in the lab to commercially producing CBG as their first cannabinoid. CBG naturally occurs at such small concentrations that it is challenging to manufacture economically with high purity levels. Yet of the more than 450 chemicals identified in the cannabis plant, CBG is one of the most compelling from the perspective of human health. CBG has the potential to be as impactful to the recreational, health and wellness landscape as CBD has become. As an anti-inflammatory, CBG has shown to outperform CBD under certain conditions. CBG is non-psychoactive which allows for a favorable global regulatory pathway. The global CBD market is estimated at $2.7 billion in 2021 and is forecast to grow at CAGR of 51% from 2021 to 2031. CBG's ability to be a substitute or even superior molecule, implies large potential addressable market opportunities.
The Company’s go to market strategy includes working with large multi-national ingredient companies, direct partnerships with cannabis MSO and LP's, cosmetic partnerships, distributor deals, direct sales to consumer-packaged goods entities and white labeling for cosmetics and/or food & beverage products.
The Company is well capitalized to execute on their business plan with over $35M in cash on their balance sheet and is led by an experienced and accomplished management team who collectively represent over $4 billion in prior company exits and $1B in prior capital raised.
News 
Market Data 
Discover 
